Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
P/B ratio for Ascendis Pharma A/S (ASND)
P/B ratio as of 2023: -44.02
According to Ascendis Pharma A/S's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -44.02. At the end of 2022 the company had a P/B ratio of 24.28.
P/B ratio history for Ascendis Pharma A/S from 2011 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -44.02 |
| 2022 | 24.28 |
| 2021 | 7.33 |
| 2020 | 8.24 |
| 2019 | 9.66 |
| 2018 | 8.01 |
| 2017 | 5.95 |
| 2016 | 2.89 |
| 2015 | 3.32 |
| 2014 | 5.75 |
| 2013 | 23.47 |
| 2012 | 99.06 |
| 2011 | 0.00 |